Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Pour, Ludek
[Clear All Filters]
2024
Pour L
,
Micheva I
,
Usenko G
,
Mikala G
,
Masszi T
,
Simeonova K
,
Thuresson M
,
Huledal G
,
Norin S
,
Bakker NA
, et al.
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk. 2024.
PubMed
Google Scholar
2023
Pour L
,
Szarejko M
,
Bila J
,
Schjesvold FH
,
Spicka I
,
Maisnar V
,
Jurczyszyn A
,
Grudeva-Popova Z
,
Hajek R
,
Usenko G
, et al.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Haematologica. 2023.
PubMed
Google Scholar
van de Donk NWCJ
,
Minnema MC
,
van der Holt B
,
Schjesvold F
,
Wu KLung
,
Broijl A
,
Roeloffzen WWH
,
Gadisseur A
,
Pietrantuono G
,
Pour L
, et al.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol. 2023.
PubMed
Google Scholar
2022
Schjesvold FH
,
Dimopoulos M-A
,
Delimpasi S
,
Robak P
,
Coriu D
,
Legiec W
,
Pour L
,
Spicka I
,
Masszi T
,
Doronin V
, et al.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Lancet Haematol. 2022.
PubMed
Google Scholar
2020
Di Bacco A
,
Bahlis NJ
,
Munshi NC
,
Avet-Loiseau H
,
Masszi T
,
Viterbo L
,
Pour L
,
Ganly P
,
Cavo M
,
Langer C
, et al.
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Eur J Haematol. 2020.
PubMed
Google Scholar
2016
Adam Z
,
Pour L
,
Krejci M
,
Ševčíková S
,
Pourová E
,
Ševčíková E
,
Král Z
,
Mayer J
.
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Vnitr Lek. 2016;62(1):25-39.
PubMed
Google Scholar
2015
Dimopoulos MA
,
Moreau P
,
Palumbo A
,
Joshua D
,
Pour L
,
Hajek R
,
Facon T
,
Ludwig H
,
Oriol A
,
Goldschmidt H
, et al.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol. 2015.
PubMed
Google Scholar
Minarik J
,
Pavlicek P
,
Pour L
,
Pika T
,
Maisnar V
,
Spicka I
,
Jarkovsky J
,
Krejci M
,
Bacovsky J
,
Radocha J
, et al.
Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy.
PLoS One. 2015;10(4):e0123866.
PubMed
Google Scholar